Alkem Laboratories Ltd.
ALKEMHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
20 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 20 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20211115 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220209 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220516 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220810 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221114 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230215 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230522 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230814 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231110 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240214 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240603 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240812 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241118 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250211 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250602 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250819 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251119 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260216 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260601 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260820 | 2026-06-30 | yes |
ALKEM
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 5,326.00 |
| 52-week range | 5087.5 – 5890.0 |
| Return 1M | -0.78% |
| Return 3M | -1.82% |
| Return 1Y | -4.48% |
| Return 3Y | 49.78% |
| Return 5Y | 33.05% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 3,740.00 |
| Other income | 153.00 |
| Total income | 3,893.00 |
| Cost of materials consumed | 910.00 |
| Purchases of stock-in-trade | 366.00 |
| Changes in inventories | -75.00 |
| Employee benefit expense | 809.00 |
| Finance costs | 47.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.50 | -0.02 |
| institutions foreign | 0.10 | 0.00 |
| institutions domestic | 0.23 | 0.01 |
| mutual funds | 0.17 | 0.01 |
| public | 0.50 | 0.02 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 20 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 3,079.00 | 3,041.00 | 2,903.00 | 2,968.00 | 3,440.00 | 3,324.00 | 2,936.00 | 3,032.00 | 3,415.00 | 3,374.00 | 3,144.00 | 3,371.00 | 4,001.00 | 3,737.00 | 3,603.00 | 3,740.00 |
| Other income | 51.00 | 45.00 | 69.00 | 66.00 | 63.00 | 94.00 | 88.00 | 120.00 | 134.00 | 93.00 | 146.00 | 136.00 | 104.00 | 143.00 | 200.00 | 153.00 |
| Total income | 3,130.00 | 3,086.00 | 2,971.00 | 3,034.00 | 3,503.00 | 3,418.00 | 3,024.00 | 3,152.00 | 3,549.00 | 3,467.00 | 3,290.00 | 3,508.00 | 4,105.00 | 3,880.00 | 3,803.00 | 3,893.00 |
| Cost of materials consumed | 816.00 | 778.00 | 771.00 | 833.00 | 825.00 | 839.00 | 799.00 | 837.00 | 902.00 | 924.00 | 777.00 | 827.00 | 906.00 | 938.00 | 895.00 | 910.00 |
| Purchases of stock-in-trade | 341.00 | 402.00 | 347.00 | 355.00 | 432.00 | 461.00 | 381.00 | 383.00 | 354.00 | 397.00 | 380.00 | 397.00 | 472.00 | 328.00 | 498.00 | 366.00 |
| Changes in inventories | 150.00 | 69.00 | 138.00 | 11.00 | 70.00 | 5.00 | -72.00 | -144.00 | -51.00 | -117.00 | 122.00 | -53.00 | 24.00 | 7.00 | -145.00 | -75.00 |
| Employee benefit expense | 571.00 | 525.00 | 503.00 | 568.00 | 555.00 | 572.00 | 506.00 | 602.00 | 610.00 | 625.00 | 616.00 | 693.00 | 710.00 | 722.00 | 712.00 | 809.00 |
| Finance costs | 25.00 | 27.00 | 29.00 | 30.00 | 30.00 | 25.00 | 27.00 | 29.00 | 28.00 | 36.00 | 28.00 | 30.00 | 35.00 | 42.00 | 54.00 | 47.00 |
| Depreciation and amortisation | 77.00 | 78.00 | 78.00 | 72.00 | 74.00 | 70.00 | 83.00 | 80.00 | 79.00 | 85.00 | 112.00 | 88.00 | 94.00 | 95.00 | 106.00 | 100.00 |
| Other expenses | 748.00 | 668.00 | 791.00 | 812.00 | 811.00 | 740.00 | 921.00 | 745.00 | 847.00 | 786.00 | 857.00 | 768.00 | 969.00 | 915.00 | 1,126.00 | 964.00 |
| Total expenses | 2,728.00 | 2,547.00 | 2,657.00 | 2,681.00 | 2,798.00 | 2,711.00 | 2,644.00 | 2,533.00 | 2,769.00 | 2,736.00 | 2,893.00 | 2,750.00 | 3,209.00 | 3,046.00 | 3,246.00 | 3,121.00 |
| Profit before exceptional items and tax | 402.00 | 539.00 | 315.00 | 353.00 | 706.00 | 706.00 | 380.00 | 619.00 | 780.00 | 731.00 | 396.00 | 758.00 | 896.00 | 834.00 | 558.00 | 772.00 |
| Exceptional items | 0.00 | 0.00 | -103.00 | 0.00 | -58.00 | -51.00 | -13.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.00 | 0.00 | -53.00 | -135.00 | 0.00 |
| Profit before tax | 402.00 | 539.00 | 212.00 | 353.00 | 648.00 | 655.00 | 367.00 | 619.00 | 780.00 | 731.00 | 396.00 | 771.00 | 896.00 | 781.00 | 423.00 | 772.00 |
| Current tax | 87.00 | 89.00 | 63.00 | 66.00 | 159.00 | 114.00 | 84.00 | 124.00 | 156.00 | 159.00 | 84.00 | 141.00 | 180.00 | 177.00 | 122.00 | 232.00 |
| Deferred tax | -32.00 | -10.00 | 81.00 | -1.00 | -126.00 | -63.00 | -21.00 | -55.00 | -78.00 | -69.00 | -11.00 | -38.00 | -64.00 | -49.00 | 50.00 | 18.00 |
| Tax expense | 55.00 | 79.00 | 144.00 | 65.00 | 33.00 | 51.00 | 63.00 | 69.00 | 78.00 | 90.00 | 73.00 | 103.00 | 116.00 | 128.00 | 171.00 | 250.00 |
| Profit for the period | 348.00 | 460.00 | 68.00 | 288.00 | 615.00 | 604.00 | 304.00 | 550.00 | 702.00 | 641.00 | 322.00 | 668.00 | 779.00 | 653.00 | 251.00 | 521.00 |
| Profit attributable to owners | 331.00 | 455.00 | 71.00 | 287.00 | 621.00 | 595.00 | 294.00 | 545.00 | 689.00 | 626.00 | 306.00 | 664.00 | 765.00 | 636.00 | 236.00 | 520.00 |
| Profit attributable to non-controlling interests | 17.00 | 5.00 | -3.00 | 1.00 | -6.00 | 9.00 | 11.00 | 5.00 | 13.00 | 15.00 | 17.00 | 4.00 | 14.00 | 17.00 | 15.00 | 1.00 |
| Other comprehensive income | 41.00 | 32.00 | -10.00 | 11.00 | 11.00 | 5.00 | -8.00 | 4.00 | 6.00 | 12.00 | -3.00 | 2.00 | 43.00 | 24.00 | 115.00 | 3.00 |
| Total comprehensive income | 388.00 | 492.00 | 57.00 | 299.00 | 626.00 | 610.00 | 297.00 | 554.00 | 708.00 | 653.00 | 320.00 | 670.00 | 822.00 | 677.00 | 366.00 | 524.00 |
| Earnings per share, basic | 27.67 | 38.03 | 5.94 | 23.98 | 51.90 | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 | 25.57 | 55.56 | 63.99 | 53.19 | 19.77 | 43.49 |
| Earnings per share, diluted | 27.67 | 38.03 | 5.94 | 23.98 | 51.90 | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 | 25.57 | 55.56 | 63.99 | 53.19 | 19.77 | 43.49 |
Annual results, as filed
| Line | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 6,431.00 | 7,357.00 | 8,344.00 | 10,634.00 | 11,599.00 | 12,668.00 | 12,965.00 | 14,712.00 |
| Other income | 96.00 | 88.00 | 104.00 | 163.00 | 216.00 | 311.00 | 494.00 | 583.00 |
| Total income | 6,527.00 | 7,445.00 | 8,449.00 | 10,797.00 | 11,815.00 | 12,978.00 | 13,458.00 | 15,296.00 |
| Cost of materials consumed | 1,567.00 | 1,811.00 | 2,132.00 | 3,226.00 | 3,057.00 | 3,295.00 | 3,440.00 | 3,565.00 |
| Purchases of stock-in-trade | 1,036.00 | 1,130.00 | 1,443.00 | 1,490.00 | 1,388.00 | 1,629.00 | 1,514.00 | 1,694.00 |
| Changes in inventories | -90.00 | 4.00 | -230.00 | -535.00 | 462.00 | 14.00 | -190.00 | -167.00 |
| Employee benefit expense | 1,192.00 | 1,362.00 | 1,505.00 | 1,963.00 | 2,131.00 | 2,201.00 | 2,454.00 | 2,837.00 |
| Finance costs | 55.00 | 55.00 | 65.00 | 52.00 | 107.00 | 112.00 | 122.00 | 161.00 |
| Depreciation and amortisation | 143.00 | 193.00 | 253.00 | 304.00 | 310.00 | 299.00 | 357.00 | 382.00 |
| Other expenses | 1,698.00 | 1,935.00 | 2,021.00 | 2,438.00 | 2,952.00 | 3,284.00 | 3,234.00 | 3,777.00 |
| Total expenses | 5,601.00 | 6,490.00 | 7,189.00 | 8,938.00 | 10,408.00 | 10,834.00 | 10,931.00 | 12,250.00 |
| Profit before exceptional items and tax | 926.00 | 955.00 | 1,260.00 | 1,859.00 | 1,408.00 | 2,145.00 | 2,527.00 | 3,046.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | -15.00 | -103.00 | -121.00 | 0.00 | -175.00 |
| Profit before tax | 926.00 | 955.00 | 1,260.00 | 1,844.00 | 1,305.00 | 2,023.00 | 2,527.00 | 2,871.00 |
| Current tax | 243.00 | 229.00 | 323.00 | 362.00 | 274.00 | 422.00 | 524.00 | 620.00 |
| Deferred tax | 45.00 | -48.00 | -212.00 | -198.00 | 24.00 | -211.00 | -213.00 | -102.00 |
| Tax expense | 288.00 | 181.00 | 110.00 | 164.00 | 298.00 | 212.00 | 311.00 | 518.00 |
| Profit for the period | 638.00 | 774.00 | 1,149.00 | 1,680.00 | 1,007.00 | 1,811.00 | 2,215.00 | 2,351.00 |
| Profit attributable to owners | 631.00 | 761.00 | 1,127.00 | 1,646.00 | 984.00 | 1,796.00 | 2,165.00 | 2,302.00 |
| Profit attributable to non-controlling interests | 7.00 | 13.00 | 22.00 | 35.00 | 23.00 | 16.00 | 50.00 | 49.00 |
| Other comprehensive income | -19.00 | 31.00 | 27.00 | 34.00 | 115.00 | 20.00 | 20.00 | 184.00 |
| Total comprehensive income | 619.00 | 805.00 | 1,176.00 | 1,714.00 | 1,122.00 | 1,832.00 | 2,235.00 | 2,535.00 |
| Earnings per share, basic | 52.77 | 63.61 | 94.26 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 |
| Earnings per share, diluted | 52.77 | 63.61 | 94.26 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 13,869.00 | 13,757.00 | 14,926.00 | 15,575.00 | 17,117.00 | 17,691.00 | 20,287.00 | 20,873.00 |
| Non-current assets | 5,277.00 | 5,027.00 | 5,264.00 | 5,163.00 | 6,008.00 | 6,745.00 | 8,161.00 | 8,662.00 |
| Current assets | 8,593.00 | 8,606.00 | 9,596.00 | 10,412.00 | 10,975.00 | 10,811.00 | 12,126.00 | 12,211.00 |
| Property, plant and equipment | 2,257.00 | 2,065.00 | 2,148.00 | 2,161.00 | 2,013.00 | 2,064.00 | 2,111.00 | 2,695.00 |
| Capital work-in-progress | 402.00 | 310.00 | 181.00 | 148.00 | 292.00 | 477.00 | 653.00 | 138.00 |
| Goodwill | 421.00 | 413.00 | 416.00 | 417.00 | 419.00 | 423.00 | 497.00 | 524.00 |
| Other intangible assets | 201.00 | 204.00 | 328.00 | 295.00 | 302.00 | 365.00 | 613.00 | 652.00 |
| Inventories | 2,785.00 | 2,608.00 | 2,541.00 | 2,661.00 | 2,912.00 | 2,922.00 | 3,007.00 | 3,333.00 |
| Trade receivables | 2,147.00 | 2,132.00 | 2,448.00 | 2,253.00 | 2,498.00 | 2,466.00 | 3,092.00 | 2,979.00 |
| Cash and cash equivalents | 241.00 | 274.00 | 321.00 | 455.00 | 413.00 | 304.00 | 226.00 | 248.00 |
| Total equity and liabilities | 13,869.00 | 13,757.00 | 14,926.00 | 15,575.00 | 17,117.00 | 17,691.00 | 20,287.00 | 20,873.00 |
| Equity | 9,368.00 | 9,435.00 | 10,225.00 | 10,714.00 | 11,910.00 | 12,434.00 | 13,811.00 | 14,349.00 |
| Equity share capital | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 |
| Other equity | 9,118.00 | 9,021.00 | 9,819.00 | 10,288.00 | 11,469.00 | 11,961.00 | 13,322.00 | 13,796.00 |
| Total liabilities | 4,501.00 | 4,322.00 | 4,701.00 | 4,860.00 | 5,207.00 | 5,257.00 | 6,477.00 | 6,524.00 |
| Non-current liabilities | 527.00 | 614.00 | 789.00 | 866.00 | 1,029.00 | 1,292.00 | 1,599.00 | 1,741.00 |
| Current liabilities | 3,975.00 | 3,707.00 | 3,912.00 | 3,995.00 | 4,171.00 | 3,959.00 | 4,878.00 | 4,783.00 |
| Borrowings, non-current | 10.00 | 70.00 | 0.00 | 40.00 | 126.00 | 311.00 | 468.00 | 492.00 |
| Borrowings, current | 1,827.00 | 1,326.00 | 1,241.00 | 1,174.00 | 1,110.00 | 752.00 | 1,494.00 | 1,131.00 |
| Trade payables | 1,069.00 | 1,165.00 | 1,172.00 | 1,748.00 | 1,886.00 | 1,839.00 | 1,887.00 | 2,244.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 564.00 | 1,682.00 | 935.00 | 1,948.00 | 942.00 | 1,913.00 | 837.00 | 1,963.00 |
| Net cash from investing activities | 339.00 | 113.00 | -625.00 | -1,009.00 | -898.00 | -1,299.00 | -1,568.00 | -1,667.00 |
| Net cash from financing activities | -889.00 | -1,761.00 | -262.00 | -1,145.00 | -321.00 | -811.00 | 463.00 | -503.00 |
| Purchase of property, plant and equipment | 132.00 | 233.00 | 116.00 | 259.00 | 307.00 | 676.00 | 396.00 | 617.00 |
| Net increase in cash | 9.00 | 42.00 | 47.00 | -207.00 | -261.00 | -186.00 | -268.00 | -222.00 |
| con:CFO.BEFORE_TAX | 681.00 | 1,956.00 | 1,245.00 | 2,355.00 | 1,171.00 | 2,417.00 | 1,264.00 | 2,592.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | -116.00 | 0.00 | 0.00 | 0.00 | -192.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| con:TAX_PAID.OPERATING | 117.00 | 273.00 | 194.00 | 407.00 | 229.00 | 504.00 | 236.00 | 629.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 1.00 | 3.00 | 2.00 | 72.00 | 9.00 | 41.00 | 108.00 | 130.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 171.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 57.16 | 57.16 | 56.74 | 56.74 | 56.74 | 56.38 | 55.66 | 55.66 | 55.13 | 53.04 | 0.51 | 0.51 | 0.51 | 0.50 |
| Domestic institutions | 16.69 | 16.34 | 17.64 | 15.91 | 15.63 | 18.57 | 19.21 | 18.01 | 19.42 | 21.80 | 0.22 | 0.22 | 0.21 | 0.23 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 16.67 | 0.17 | 0.16 | 0.16 | 0.17 |
| Insurance companies | 6.00 | 3.98 | 3.49 | 2.86 | 2.75 | 2.85 | 3.18 | 2.83 | 3.20 | 3.62 | 0.04 | 0.04 | 0.04 | 0.04 |
| Foreign institutions | 4.44 | 5.64 | 6.03 | 8.49 | 9.11 | 8.69 | 9.02 | 10.15 | 9.41 | 9.11 | 0.09 | 0.10 | 0.10 | 0.10 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | — |
| Public | 42.84 | 42.84 | 43.26 | 43.26 | 43.26 | 43.62 | 44.34 | 44.34 | 44.87 | 46.96 | 0.49 | 0.49 | 0.49 | 0.50 |
| Non-institutional | 21.70 | 20.86 | 19.59 | 18.86 | 18.52 | 16.36 | 16.10 | 16.18 | 16.05 | 16.05 | 0.17 | 0.17 | 0.17 | 0.17 |
| Shares outstanding | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 | 119565000 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Ascend Laboratories, LLC | Step down subsidiary | Any other transaction, Sale of goods or services | 8,803,830,000.00 | 5 |
| Alkem Medtech Private Limited | Subsidiary | Any other transaction, Investment | 2,021,370,000.00 | 2 |
| Pharmacor Pty Limited | Subsidiary | Any other transaction, Sale of goods or services | 1,171,800,000.00 | 5 |
| Enzene Inc | Subsidiary | Any other transaction, Investment | 986,580,000.00 | 2 |
| Ascend Laboratories SpA | Subsidiary | Any other transaction, Sale of goods or services | 803,830,000.00 | 4 |
| The Pharmanetwork, LLP | Subsidiary | Sale of goods or services | 777,440,000.00 | 1 |
| Enzene Biosciences Limited | Subsidiary | Any other transaction, Purchase of goods or services | 722,420,000.00 | 4 |
| Cachet Pharmaceuticals Private Limited | Subsidiary | Any other transaction, Purchase of goods or services | 618,530,000.00 | 7 |
| Pharma Network SpA | Step down subsidiary | Any other transaction, Sale of goods or services | 559,910,000.00 | 3 |
| Ascend GmbH | Subsidiary | Sale of goods or services | 477,810,000.00 | 1 |
| Indchemie Health Specialities Private Limited | Subsidiary | Any other transaction, Purchase of goods or services | 444,310,000.00 | 4 |
| Ascend Laboratories (UK) Limited | Subsidiary | Sale of goods or services | 436,500,000.00 | 1 |
| The Pharma Network, LLC | Subsidiary | Purchase of goods or services, Sale of goods or serv | 253,720,000.00 | 2 |
| Alkem Foundation | Subsidiary | Any other transaction | 248,530,000.00 | 1 |
| Mr. Basudeo Narain Singh | Key Management Personnel | Any other transaction, Remuneration | 125,150,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-20 | Q1FY27 | ALKEM LABORATORIES LIMITED | Read the call |
| 2026-06-01 | Q4FY26 | ALKEM LABORATORIES LIMITED | Read the call |
| 2026-02-16 | Q3FY26 | ALKEM LABORATORIES LIMITED | Read the call |
| 2025-11-19 | H1FY26 | ALKEM LABORATORIES LIMITED | Read the call |
| 2025-08-19 | Q1FY26 | ALKEM LABORATORIES LIMITED | Read the call |
| 2025-06-02 | Q4FY25 | ALKEM LABORATORIES LIMITED | Read the call |
| 2025-02-11 | Q3FY25 | ALKEM LABORATORIES LIMITED | Read the call |
| 2024-11-18 | Q2FY25 | ALKEM LABORATORIES LIMITED | Read the call |
| 2024-08-12 | Q1FY25 | ALKEM LABORATORIES LIMITED | Read the call |
| 2024-06-03 | Q4FY24 | SERVICES | Read the call |
| 2024-02-14 | Q3FY24 | ALKEM LABORATORIES LIMITED | Read the call |
| 2023-11-10 | Q2FY24 | FINANCIAL SERVICES LIMITED, LABORATORIES | Read the call |
| 2023-08-14 | Q1FY24 | ALKEM, ALKEM LABORATORIES, BUSINESS – ALKEM LABORATORIES, DIVISION – ALKEM LABORATORIES, L | Read the call |
| 2023-05-22 | Q4FY23 | ALKEM LABORATORIES LIMITED | Read the call |
| 2023-02-15 | Q3FY23 | ALKEM, ALKEM LABORATORIES, BUSINESS - ALKEM LABORATORIES, DIVISION - ALKEM LABORATORIES, F | Read the call |
| 2022-11-14 | Q2FY23 | Read the call | |
| 2022-08-10 | Q1FY23 | ALKEM LABORATORIES, BUSINESS, ALKEM LABORATORIES, DIVISION, ALKEM LABORATORIES, FINANCIAL | Read the call |
| 2022-05-16 | Q4FY22 | ALKEM, ALKEM LABORATORIES, BUSINESS, ALKEM LABORATORIES, CHOR, DIVISION, ALKEM LABORATORIE | Read the call |
| 2022-02-09 | Q3FY22 | ALKEM, ALKEM LABORATORIES, BUSINESS - ALKEM LABORATORIES, DIVISION - ALKEM LABORATORIES, L | Read the call |
| 2021-11-15 | Q2FY22 | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | So we want to invest more into R&D or biosimilar and some amount of CapEx will also go into biosimilar business because U.S. is a big opportunity for … | — | — | — | So capex is going to start from this year. | So, I think some of those kinds of opportunities we have our investments to make which is a mix of R&D as well as some of the CAPEX that we may have t… | 500 crores CAPEX cumulative will be how much? | — |
| Capital allocation | We are looking at various opportunities of deploying balance sheet cash, whether it means acquisition, whether it means putting it up into newer oppor… | And so this particular acquisition give us a manufacturing capability also because we didn't have any manufacturing setup for our ortho business. | Since we have made a major acquisition announcement today for Alkem Medtech, we also have our MD, Mr. Sandeep Singh, with us on the call, who will thr… | We continue to be the same, DNA has not changed, we are conservative, we will do what know to do best and so no large acquisition plans Prakash bhai. | Actually, declaring dividend is not in our authority, sir. | So, that's how we plan to deploy cash, but of course dividend Alkem Laboratories Limited May 29, 2024 payout, we have always been within the range of … | And also, the MedTech business will be, we have started, we have just completed the acquisition of Bombay Ortho, and there will be some time it will t… | We have -- I spoke about a few years ago, we had restructured the businesses, and that's paying very good dividend in terms of the overall growth that… |
| Costs | So it's a function of both the reduction in the raw material cost as well as the mix, so that's the geography mix and the portfolio mix, which is cont… | So for our business, given that we have some exports, but we also probably import some raw materials given you have a large India business. | — | Sir, one question on the cost pressure that you have mentioned, so raw material as the percentage of sales increased materially, you had talked about … | I understand that we might be seeing some softening in the input cost and the freight has also come down. | So, sometimes if we are more cost efficient on one side, there may be a scenario that we see an increase on some of the cost side of certain raw mater… | — | What type of capital allocation and risk management framework have been applied in '26, '27 to balance dividend payouts with funding for R&D in biosim… |
| Debt and cash | You've announced INR35 dividend that is broadly only a quarter's cash flow. | — | But definitely -- I think at operations level, they will be cash flow positive. | — | And secondly, If you refer to your cash flow statement, it refers to an issuance of preference shares, which was mid to an inflow of close to INR161 c… | — | And when you see your working capital days, it has increased in FY'25 versus FY'24. | — |
| Demand | If you can provide an update on the pipeline and what are our plans going forward, probably in the medium term, next 2 to 3 years, how are we looking … | — | And as a result of this, this company has a very strong product pipeline. | So, first is productivity, second, of course, the main therapies which dominate chronic is cardiac and diabeto, so on a diabeto front, we have a very … | So R&D, obviously, we continue to see uptrend in recent quarters because of your progress in pipeline products, etcetera. | So, when you think about growth next year at around 10%, given that you have large NLEM portfolio where there is no price increase, are you banking on… | So how is anti-infective seasonal demand looking up because I think we are already into rain etc.? | May 28, 2026 The outlook, as we enter FY '27, we strive to drive the growth and profitability with continued focus on strengthening execution, improvi… |
| Guidance | So as we have given previously guidance of around 16% to 17% and looking at our YTD performance, where we are at 18.9%, but as we all know that Q4 tra… | In 9 months, it's 21.6%, so it seems like you are on course to sort of beat that number if you can give a revised guidance for fiscal '25? | So I think put together, as of now, we are looking at, say, a similar guidance on the gross margin, maybe 0.5 to 1 percentage basis points here and th… | My question is on the India business, so I don’t know if you have already shared, but given that we are heading on a strong base of last year, are we … | We expect to save our operating expenses to the tune of INR100 crores or INR110 crores. | Sir, would you like to provide any broad outlook for FY'25 in terms of revenue growth and profitability? | So we saw a strong Q4 and we expect similar growth trajectories to continue even in the coming quarters. | While these are very early trends, but I'm happy to share that in the most recent IQVIA report, we could garner a market -- unit market share of aroun… |
| Margin | Our EBITDA margin saw significant improvement by 160 basis points. | February 07, 2025 month basis, INR21,208 million, resulting in an EBITDA margin of 21.6% and an increase of 15% Y-o-Y. | And number four, that is going to drive the margin going forward. | New launches traditionally come at a better margin profile. | We understand that our EBITDA margin for the quarter and year is subdued, and we are working towards that. | In terms of gross margins, we maintain we will be within the range of both the gross margin as well as EBITDA as to what we are currently. | However, EBITDA increased by 11.9% YOY to Rs. | We got operating leverage and continued our cost discipline, which contributed to a meaningful margin expansion. |
| People | — | — | And what kind of utilization it is currently working? | I assume that you are asking about utilization of those digitals and all, so yes, there will be slight change to reach masses through digital media an… | — | You mentioned you are broadly done in terms of hiring medical representative in sector. | 500 crores of sales from the CDMO business at full capacity utilization. | Sir, secondly, coming to the domestic formulation market, if you could share the number of MRs, attrition rate and what -- how do you think about scal… |
| Pricing | So that will lead to even better pricing in the market, and that's helping us in getting better margins out of U.S. market. | There is a lot of pressure on the pricing and competition. | We are just waiting and seeing how the market pricing would unfold. | While we had good number of new product launches during the year, some of which had limited competition, but significant pricing pressure completely o… | And then about the U.S., what about the pricing scenario over there? | So, during the previous years, especially during COVID times, we had seen a very significant upsurge in the pricing of some of the commodity APIs whic… | So I think that will decide on the pricing strategy as to exactly how we would have to price the product, and if we are working on these products now,… | My first question to Mr. Sandeep is, what type of strategic levers are you prioritizing in FY '26, '27 to expand Alkem's domestic formulation leadersh… |
| Revenue growth | We had a Y-o-Y revenue growth of approximately 9%. | Q3 FY '25 net profit was INR6,258 million with a Y-o-Y growth of 5.2%, and for 9 months was INR18,596 million with a Y-o-Y growth of 23.8%. | We are seeing good revenue growth across our core markets. | Apart from the US, other international markets delivered a robust year-on-year growth of 35% during the year with healthy performance in the markets o… | Last quarter, the cardiac growth was close to 1.8%. | I have always maintained that our revenue growth will be in line with the market growth. | 1,29,645 million with a YOY growth of 2.3%. | In Q4, our total revenue from operations was INR36,033 million with a Y-o-Y growth of 14.6% India sales were INR23,245 million with a Y-o-Y growth of … |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2022-02-09 | Q3FY22 | ALKEM LABORATORIES | February 04, 2022 price our price vis-à-vis our peer price and all this but generally our price increase is in the range of 4% to 5% definitely this time it is going to be little bit more so you can assume around 5% to 6% we expect to take price increase and volume we are somewhere close to double somewhere close to 7% to 8% I think there we may need to realign and there we can have 1% or 2% lesser compared to it. |
| 2023-02-15 | Q3FY23 | ALKEM LABORATORIES | February 10, 2023 that the earlier guidance of 15% EBITDA margin achievement in FY2023 is now looking a bit challenging, if you can update on that? |
| 2025-08-19 | Q1FY26 | ALKEM LABORATORIES LIMITED | That's why our guidance of around 19.5% initially, which was there, which as of now, I'm staying put, and we'll wait for 1 or 2 more quarters to really revise it upwards, if at all. |
| 2025-11-19 | H1FY26 | ALKEM LABORATORIES LIMITED | So that's how vis-a-vis the earlier guidance of keeping it at 19.5%. |
| 2025-11-19 | H1FY26 | ALKEM LABORATORIES LIMITED | So going forward, Q3 and Q4, we expect opex to be around INR50 crores and revenue to be around INR20 crores for the quarter because we have just started the plant. |
| 2026-06-01 | Q4FY26 | ALKEM LABORATORIES LIMITED | While these are very early trends, but I'm happy to share that in the most recent IQVIA report, we could garner a market -- unit market share of around 11% and we expect it to go up even further in the coming months. |
| 2026-06-01 | Q4FY26 | ALKEM LABORATORIES LIMITED | In the current scenario, we have touched a 20.4% kind of growth like-to-like, we would -- we should be within the range of 20% to 21%. |